Gastric cancer marker and application thereof

The invention relates to a gastric cancer marker and application thereof, in particular to application of at least one of a C10orf71 gene, a C10orf71 protein and a C10orf71 gene detection primer kit in the preparation of a product for predicting the response of a GC patient to neoadjuvant chemotherapy. It is determined for the first time that C10orf71 gene mutation is a key molecular feature withcancer in response to neoadjuvant chemotherapy. Based on the technical scheme, neoadjuvant chemotherapy has advantages in improving prognosis and determining responsive patients before treatment begins, and better therapeutic schemes can be developed. The scheme is an important step for optimizing therapeutic strategies for individual patients with GC. 本发明涉及一种胃癌标志物及其应用，特别是C10orf71基因、C10orf71蛋白、C10orf71基因检测引物试剂盒中的至少一种在制备用于预测GC患者对新辅助化疗的响应的产品中的应用。本发明首次确定了C10orf71基因突变为与肿瘤对新辅助化疗响应的关键分子特征，基于本发明的技术方案，新辅助化学疗法在改善预后以及在治疗开始之前确定响应性患者方面具有优势，因此可以制定更好的治疗方案。本发明的方案针对个别GC患者优化治疗策略的重要一步。